Scopus Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.04
- Today's High:
- $0.04
- Open Price:
- $0.04
- 52W Low:
- $0.031
- 52W High:
- $0.51
- Prev. Close:
- $0.04
- Volume:
- 732
Company Statistics
- Market Cap.:
- $2.53 million
- Book Value:
- -0.238
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -538.06%
- Return on Equity TTM:
- -1559.6%
Company Profile
Scopus Biopharma Inc had its IPO on 2020-12-16 under the ticker symbol SCPS.
The company operates in the Healthcare sector and Biotechnology industry. Scopus Biopharma Inc has a staff strength of 13 employees.
Stock update
Shares of Scopus Biopharma Inc opened at $0.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.04 - $0.04, and closed at $0.04.
This is a 0% increase from the previous day's closing price.
A total volume of 732 shares were traded at the close of the day’s session.
In the last one week, shares of Scopus Biopharma Inc have increased by 0%.
Scopus Biopharma Inc's Key Ratios
Scopus Biopharma Inc has a market cap of $2.53 million, indicating a price to book ratio of 2.4153 and a price to sales ratio of 0.
In the last 12-months Scopus Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-9341912. The EBITDA ratio measures Scopus Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Scopus Biopharma Inc’s operating margin was 0% while its return on assets stood at -538.06% with a return of equity of -1559.6%.
In Q2, Scopus Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Scopus Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.31 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scopus Biopharma Inc’s profitability.
Scopus Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0721. Its price to sales ratio in the trailing 12-months stood at 0.
Scopus Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $497554.00
- Total Liabilities
- $11.00 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Scopus Biopharma Inc ended 2024 with $497554.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $497554.00 while shareholder equity stood at $-9451751.00.
Scopus Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $11.00 million in other current liabilities, in common stock, $-58131350.00 in retained earnings and $0 in goodwill. Its cash balance stood at $362097.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Scopus Biopharma Inc’s total current assets stands at $495854.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, Scopus Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Scopus Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.04
- 52-Week High
- $0.51
- 52-Week Low
- $0.031
- Analyst Target Price
- $12
Scopus Biopharma Inc stock is currently trading at $0.04 per share. It touched a 52-week high of $0.51 and a 52-week low of $0.51. Analysts tracking the stock have a 12-month average target price of $12.
Its 50-day moving average was $0.05 and 200-day moving average was $0.08 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.
Around 1868.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Scopus Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.